Abstract | AIM: Activation of protein kinase C (PKC) is thought to play an important role in the pathogenesis of diabetic microvascular complications. PKC-beta is elevated in hyperglycaemic conditions, both in vivo and in vitro. In this study, pharmacological effects of a novel PKC-beta isoform selective inhibitor, JTT-010 ((2R)-3-(2-aminomethyl-2,3-dihydro-1H-3a-azacyclopenta(a)inden-8-yl)-4-phenylaminopyrrole-2,5-dione monomethanesulphonate), on diabetic neuropathy were examined. METHODS: PKC inhibitory activity of JTT-010 was evaluated with an enzyme assay. For the in vivo study, streptozotocin (STZ)-induced diabetic rats were treated with JTT-010 for 12 weeks and tail/sciatic nerve conduction velocity (NCV) evaluated. Hyper/hypoalgesia was evaluated using tail-flick and formalin tests. RESULTS:
JTT-010 inhibited PKC-betaI and -betaII with IC50 values of 4.0 and 2.3 nm respectively. For other PKC isoforms, IC50 values were 54 nm or greater. In STZ-induced diabetic rats showing a reduction in tail/sciatic nerve conduction velocities, JTT-010 (0.3-3 mg/kg) ameliorated the reduction of these velocities. In a formalin test, STZ-induced diabetic rats had hyperalgesia in the first phase. JTT-010 reduced nociceptive response at doses of 0.1 mg/kg or higher. Furthermore, STZ-induced diabetic rats showed hypoalgesia in the second phase of the formalin test and tail-flick test. JTT-010 also ameliorates these symptoms at doses of 0.1 mg/kg or higher. CONCLUSIONS: These observations suggest that PKC-beta contributes not only to diabetic hyperalgesia, but also to hypoalgesia and also contributes to defects in NCV. PKC-beta inhibitor, JTT-010, may be beneficial in suppressing the development of diabetic nerve dysfunction, including hyperalgesia and hypoalgesia.
|
Authors | T Sasase, H Yamada, K Sakoda, N Imagawa, T Abe, M Ito, S Sagawa, M Tanaka, M Matsushita |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 7
Issue 5
Pg. 586-94
(Sep 2005)
ISSN: 1462-8902 [Print] England |
PMID | 16050952
(Publication Type: Journal Article)
|
Chemical References |
- (2R)-3-(2-aminomethyl-2,3-dihydro-1H-3a-azacyclopenta(a)inden-8-yl)-4-phenylaminopyrrole-2,5-dione monomethanesulphonate
- Indans
- Pyrroles
- Protein Kinase C
- Protein Kinase C beta
|
Topics |
- Animals
- Diabetes Mellitus, Experimental
(complications, enzymology, physiopathology)
- Diabetic Neuropathies
(enzymology, physiopathology, prevention & control)
- Hyperalgesia
(enzymology, physiopathology, prevention & control)
- Hypesthesia
(enzymology, physiopathology, prevention & control)
- Indans
(pharmacology, therapeutic use)
- Male
- Neural Conduction
(drug effects)
- Protein Kinase C
(antagonists & inhibitors, metabolism, physiology)
- Protein Kinase C beta
- Pyrroles
(pharmacology, therapeutic use)
- Rats
- Rats, Sprague-Dawley
- Sciatic Nerve
(enzymology, physiopathology)
|